Last updated: February 16, 2026
What Is NDC 00597-0152?
NDC 00597-0152 is Aducanumab, marketed commercially as Aduhelm. It is a monoclonal antibody approved by the FDA in June 2021 for the treatment of Alzheimer’s disease, targeting amyloid beta plaques.
Market Size and Demand Drivers
-
Prevalence: Alzheimer’s affects approximately 6.2 million Americans aged 65 and older, with projections reaching 12.7 million by 2050 [1].
-
Treatment Market: The Alzheimer’s drug market was valued at ~$9 billion in 2022, with Aduhelm accounting for a significant share post-approval.
-
Prescribing Trends: As of 2023, estimates suggest around 200,000 patients could be eligible for Aduhelm treatment in the U.S. based on FDA’s criteria and insurance reimbursement policies [2].
-
Reimbursement & Access: Medicare’s decision not to cover Aduhelm broadly limited initial adoption but recent policy adjustments and expanded access could influence demand upward.
Competitive Landscape
-
Existing Treatments: Cure Alzheimer’s (Lecanemab, EVGL, Eisai/Biogen), which showed more promising safety profiles and effectiveness, has created a competitive pressure on Aduhelm.
-
Innovation & Pipeline: Several monoclonal antibodies targeting amyloid beta are in late-stage development, with some promising better efficacy and fewer side effects.
-
Market Share Trajectory: Predictions indicate Aduhelm could capture 20-30% of the Alzheimer’s biologic market within 3-5 years, contingent on approval expansions and payer coverage.
Pricing Overview
-
Initial Price: The list price set was approximately $56,000 per year for Aduhelm [3].
-
Pricing Adjustments: A discounted billing model was introduced for Medicare patients with the aim to improve affordability. Commercial insurance coverage is variable.
-
Cost-Effectiveness: Limited real-world data suggest the drug’s high cost limits favorable cost-benefit ratios, impacting sustained utilization rates.
Price Projections (2023-2027)
| Year |
Estimated Average Price |
Key Drivers |
Notes |
| 2023 |
$55,000 - $59,000 |
Market entry, reimbursement negotiations |
Price stabilizes as insurer negotiations mature |
| 2024 |
$52,000 - $55,000 |
Payer pressure, demand stabilization |
Competition begins impacting pricing |
| 2025 |
$48,000 - $52,000 |
Increased competition, approval of alternatives |
Off-label use limits growth |
| 2026 |
$45,000 - $50,000 |
Market maturation, policy shifts |
Potential price caps or discounts |
| 2027 |
$42,000 - $47,000 |
Approaching patent expiry, biosimilar threat |
Evolving market with new entrants |
Risks and Factors Impacting Price and Market Size
-
Regulatory Environment: Future approvals for broader patient populations or additional indications could increase market size.
-
Payer Policies: Coverage restrictions or formulary decisions could constrain revenue.
-
Efficacy & Safety Data: Emerging data on clinical benefits and adverse effects will influence prescriber willingness.
-
Patent and Biosimilar Competition: Patent expiry around 2030 could lead to biosimilar entrants, reducing prices significantly.
Conclusion
Aducanumab (NDC 00597-0152) faces a limited initial market primarily driven by high costs, payer restrictions, and competition. The drug’s price is projected to decline gradually over five years, contingent on market dynamics, regulatory changes, and the competitive landscape. Adequate reimbursement strategies and new clinical data will be critical to sustaining its market presence.
Key Takeaways
- The initial list price was ~$56,000 annually; real-world prices may vary due to discounts and insurer negotiations.
- Market size is constrained by patient eligibility, reimbursement policies, and competition.
- Penetration is expected to grow slowly, with prices decreasing by approximately 20-25% over five years.
- Biosimilar competition and patent expiry are imminent risks to sustained pricing power.
- Drugs like Lecanemab could further pressure Aduhelm’s market share, affecting pricing.
FAQs
Q1: What is the current FDA status for Aduhelm?
A1: Approved in June 2021 for Alzheimer’s disease; ongoing reviews for expanded indications.
Q2: How does payer coverage affect Aduhelm’s pricing?
A2: Limited coverage restricts utilization, which can suppress revenue and lead to price negotiations or discounts.
Q3: What is the competitive outlook for Alzheimer’s monoclonal antibodies?
A3: Lecanemab, approved in early 2023, provides a more favorable safety profile, challenging Aduhelm’s market share.
Q4: When is patent expiry expected?
A4: Patent protections are expected to expire around 2030, opening potential for biosimilar competition.
Q5: How might new clinical data influence the market?
A5: Positive efficacy and safety data could boost use, while adverse findings could further limit sales.
Citations
- Alzheimer’s Association. 2022 Alzheimer’s Disease Facts and Figures.
- IQVIA. 2023 Alzheimer’s therapeutic market report.
- Biogen. Aduhelm pricing statements, 2021.
